Terlipressin bests placebo in type 1 hepatorenal syndrome

Terlipressin bests placebo in type 1 hepatorenal syndrome

(HealthDay)—For patients with type 1 hepatorenal syndrome (HRS-1), terlipressin is more effective than placebo for reversal of HRS, according to a study published in the March 4 issue of the New England Journal of Medicine.

Florence Wong, M.B.B.S., from the University of Toronto, and colleagues conducted a phase 3 trial to confirm the efficacy and safety of terlipressin plus albumin in 300 adults with HRS-1. Patients were randomly assigned to receive either terlipressin (199 ) or placebo (101 patients) for up to 14 days; concomitant use of albumin was strongly recommended in both groups. Verified reversal of HRS was the primary end point.

The researchers found that 32 and 17 percent of patients in the terlipressin and placebo groups, respectively, had verified reversal of HRS. Three of the four prespecified secondary end points were met by significantly more patients in the terlipressin group than in the . Liver transplantation had been performed in 23 and 29 percent of patients in the terlipressin and placebo groups, respectively, at day 90, and death occurred in 51 and 45 percent, respectively. Compared with placebo, there were more adverse events reported in the terlipressin group. Death within 90 days due to respiratory disorders occurred in 11 and 2 percent of patients in the terlipressin and groups, respectively.

"Overall, the results of the CONFIRM study are in accordance with the data from previous clinical trials that provide evidence that terlipressin improves in patients with HRS-1," the authors write.

The study was funded by Mallinckrodt Pharmaceuticals, the manufacturer of terlipressin.


Explore further

Terlipressin therapy can induce hyponatremia

More information: Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Journal information: New England Journal of Medicine

Copyright © 2020 HealthDay. All rights reserved.

Citation: Terlipressin bests placebo in type 1 hepatorenal syndrome (2021, March 4) retrieved 18 May 2021 from https://medicalxpress.com/news/2021-03-terlipressin-bests-placebo-hepatorenal-syndrome.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
1 shares

Feedback to editors

User comments